CL2021000627A1 - Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular - Google Patents

Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular

Info

Publication number
CL2021000627A1
CL2021000627A1 CL2021000627A CL2021000627A CL2021000627A1 CL 2021000627 A1 CL2021000627 A1 CL 2021000627A1 CL 2021000627 A CL2021000627 A CL 2021000627A CL 2021000627 A CL2021000627 A CL 2021000627A CL 2021000627 A1 CL2021000627 A1 CL 2021000627A1
Authority
CL
Chile
Prior art keywords
joint
treatment
pharmaceutical compositions
compositions suitable
joint pain
Prior art date
Application number
CL2021000627A
Other languages
English (en)
Spanish (es)
Inventor
Yun-Long Tseng
Sheue-Fang Shih
Po-Chun Chang
Lo Chang
Original Assignee
Tlc Biopharmaceuticals Inc
Taiwan Liposome Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tlc Biopharmaceuticals Inc, Taiwan Liposome Co Ltd filed Critical Tlc Biopharmaceuticals Inc
Publication of CL2021000627A1 publication Critical patent/CL2021000627A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2021000627A 2018-09-16 2021-03-15 Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular CL2021000627A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862731941P 2018-09-16 2018-09-16

Publications (1)

Publication Number Publication Date
CL2021000627A1 true CL2021000627A1 (es) 2021-09-10

Family

ID=68084954

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000627A CL2021000627A1 (es) 2018-09-16 2021-03-15 Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular

Country Status (15)

Country Link
US (1) US12208104B2 (enExample)
EP (1) EP3849522A1 (enExample)
JP (1) JP7634476B2 (enExample)
KR (1) KR20210060559A (enExample)
CN (1) CN112702993A (enExample)
AU (1) AU2019339528B2 (enExample)
BR (1) BR112021004880A2 (enExample)
CA (1) CA3112234A1 (enExample)
CL (1) CL2021000627A1 (enExample)
IL (1) IL281513B1 (enExample)
MX (1) MX2021003030A (enExample)
SG (1) SG11202102400PA (enExample)
TW (1) TWI843751B (enExample)
WO (1) WO2020056399A1 (enExample)
ZA (1) ZA202101688B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023537474A (ja) 2020-08-05 2023-09-01 ティーエルシー バイオファーマシューティカルズ、インク. 疼痛制御のための関節内コルチコステロイドの医薬組成物
EP4706666A1 (en) * 2023-05-05 2026-03-11 Xiangya Hospital, Central South University Use of magnesium hydroxide in preparation of drug for treating arthralgia
IL327816A (en) * 2023-11-03 2026-06-01 Taiwan Liposome Co Ltd Liposomal composition of intra-articular corticosteroid for pain control

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152962A1 (en) * 2002-06-12 2005-07-14 Metselaar Josbert M. Composition for treatment of inflammatory disorders
EP1371362A1 (en) * 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
AU2013216861B2 (en) 2012-02-10 2017-05-18 Tlc Biopharmaceuticals, Inc Pharmaceutical compositions to reduce complications of ocular steroid
BR112015000174A2 (pt) * 2012-07-05 2017-06-27 Taiwan Liposome Co Ltd método para o tratamento da artrite

Also Published As

Publication number Publication date
IL281513B1 (en) 2026-07-01
IL281513A (en) 2021-04-29
AU2019339528A1 (en) 2021-04-15
AU2019339528B2 (en) 2025-01-30
ZA202101688B (en) 2024-06-26
TW202023569A (zh) 2020-07-01
WO2020056399A1 (en) 2020-03-19
EP3849522A1 (en) 2021-07-21
TWI843751B (zh) 2024-06-01
KR20210060559A (ko) 2021-05-26
US12208104B2 (en) 2025-01-28
CA3112234A1 (en) 2020-03-19
US20210338688A1 (en) 2021-11-04
CN112702993A (zh) 2021-04-23
JP2022500364A (ja) 2022-01-04
SG11202102400PA (en) 2021-04-29
MX2021003030A (es) 2021-05-27
BR112021004880A2 (pt) 2021-06-01
JP7634476B2 (ja) 2025-02-21

Similar Documents

Publication Publication Date Title
PY2054376A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
DOP2025000288A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
PE20242299A1 (es) Composiciones agonistas de gip/glp1
UY38221A (es) Inhibidores de proteínas ras con g12c mutantes
MX2021006575A (es) Composiciones y metodos para el tratamiento de trastornos del higado.
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
MX376312B (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash
CL2022000005A1 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
DOP2019000070A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
MX2021014371A (es) Composiciones que comprenden acidos grasos cetilados y uso de las mismas en el tratamiento de la artritis y de afecciones inflamatorias de las articulaciones.
CL2021000282A1 (es) Inhibidores de ckd8/19
MX2021003030A (es) Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
CL2022001323A1 (es) Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x
DOP2019000071A (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos
MX2022007174A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
CO2020012484A2 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
AR114282A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida (“tcd”)
AR112530A1 (es) Composiciones farmacéuticas de ajoeno o un análogo o derivado de éste y sus usos
AR110598A1 (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles